Sarcoidosis Analysis report covers 6 drugs currently in different phases of development. Sarcoidosis is an inflammatory disease characterised by growth and inflammation of granulomas in various organs, predominantly in the lungs and intrathoracic lymph nodes. The exact cause of sarcoidosis is not known. Symptoms of the sarcoidosis differ as per the organ affected by the disease. However, general symptoms include fatigue, chills and fever, swollen lymph nodes and weight loss. Tests for the diagnosis of the disease include chest x-ray, pulmonary function test, blood test, biopsy, bronchoalveolar lavage, gallium scanning, kveim test and slit-lamp examination.
The report provides Sarcoidosis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Araim Pharmaceuticals, Inc., Novartis, OncoArendi Therapeutics, Reata Pharmaceuticals, Inc. and Relief Therapeutics among others.
Scope:
* There may be changes in final report as per data availability.